A compound having the general formula, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, wherein X 10 is NR 15, N(R 15)C, C NR 15, O, C, C O, OC; N(R 15)SO 2, SO 2 N(R 15), S, SO, or SO 2; R 10 is -H, a -C 1-6 alkyl group or a -C -C 1-6 alkyl group; R 11 is -H, a -C 1-6 alkyl group, or a -C 1-6 alkyl group which is substituted by one or more halogen atoms; R 12 is -H, a -C 1-6 alkyl group, or a -C 1-6 alkyl group which is substituted by one or more halogen atoms; or wherein R 11 and R 12 can be joined together to form a 3- to 7-membered carbo- or heterocyclic ring; R 13 is -R 16, or -X 10 -R 16; R 14 is -H, -(optionally substituted C 1-6 alkyl), -(optionally substituted C 3-7 cycloalkyl), -(optionally substituted aryl), -C 1-4 alkyl-(optionally substituted C 3-7 cycloalkyl), or -C 1-4 alkyl-(optionally substituted aryl); R 15 is -H, -(optionally substituted C 1-6 alkyl), -(optionally substituted C 3-7 cycloalkyl), -(optionally substituted aryl), -C 1-4 alkyl-(optionally substituted C 3-7 cycloalkyl), or -C 1-4 alkyl-(optionally substituted aryl); R 16 is selected from wherein X is absent, CH 2, NH, C NH, S or O; Y is CH 2; Z is O or S; and R is independently selected from -H, -C 1-6 alkyl, -CF 3, -Hal, -CN, -OH, and -O-C 1-6 alkyl; R 17 is -H, -C 1-6 alkyl, or -(CH 2 CH 2 O) r H; R 18 is -H, or -C 1-6 alkyl; R** is independently selected from -C 1-6 alkyl, -C -C 1-6 alkyl, -Hal, -CF 3, -CN, -COOR 17, -OR 17, -(CH 2) q NR 17 R 18, -C -NR 17 R 18, and -NR 17 -C -C 1-6 alkyl; R* is independently selected from -H, -C 1-6 alkyl, and -C 3-7 cycloalkyl; q is 0 to 4; and r is 1 to 3; wherein the optionally substituted alkyl group, optionally substituted aryl group and/or optionally substituted cycloalkyl group in R 14 and R 15 can be substituted with one or more substituents R**; wherein a prodrug is a compound in which R 10 is replaced by C OR 19; or C R 19; wherein R 19 is selected from C 5-10 aryl, C 1-6 alkyl-C 5-10 aryl, C 1-6 alkyl, C 1-6 alkyl(-O-C 1-6 alkyl) n (with n = 1 to 30), C 1-6 alkyl-C OR, and C 5-10 aryl-C OR; and the group R is H or C 1-6 alkyl. X 10 is NR 15, N(R 15)C, C NR 15, O, C, C O, OC; N(R 15)SO 2, SO 2 N(R 15), S, SO, or SO 2; R 10 is -H, a -C 1-6 alkyl group or a -C -C 1-6 alkyl group; R 11 is -H, a -C 1-6 alkyl group, or a -C 1-6 alkyl group which is substituted by one or more halogen atoms; R 12 is -H, a -C 1-6 alkyl group, or a -C 1-6 alkyl group which is substituted by one or more halogen atoms; or wherein R 11 and R 12 can be joined together to form a 3- to 7-membered carbo- or heterocyclic ring; R 13 is -R 16, or -X 10 -R 16; R 14 is -H, -(optionally substituted C 1-6 alkyl), -(optionally substituted C 3-7 cycloalkyl), -(optionally substituted aryl), -C 1-4 alkyl-(optionally substituted C 3-7 cycloalkyl), or -C 1-4 alkyl-(optionally substituted aryl); R 15 is -H, -(optionally substituted C 1-6 alkyl), -(optionally substituted C 3-7 cycloalkyl), -(optionally substituted aryl), -C 1-4 alkyl-(optionally substituted C 3-7 cycloalkyl), or -C 1-4 alkyl-(optionally substituted aryl); R 16 is selected from X is absent, CH 2, NH, C NH, S or O; Y is CH 2; Z is O or S; and R is independently selected from -H, -C 1-6 alkyl, -CF 3, -Hal, -CN, -OH, and -O-C 1-6 alkyl; R 17 is -H, -C 1-6 alkyl, or -(CH 2 CH 2 O) r H; R 18 is -H, or -C 1-6 alkyl; R** is independently selected from -C 1-6 alkyl, -C -C 1-6 alkyl, -Hal, -CF 3, -CN, -COOR 17, -OR 17, -(CH 2) q NR 17 R 18, -C -NR 17 R 18, and -NR 17 -C -C 1-6 alkyl; R* is independently selected from -H, -C 1-6 alkyl, and -C 3-7 cycloalkyl; q is 0 to 4; and r is 1 to 3;